StockWatch
·

INDO RAMA SYNTHETICS (INDIA) LTD.

BSE: 500207

P/L Snapshot

Q2 FY27 · standalone

vs Q1 FY27·vs Q2 FY26
Revenue
1.3K
+52.1%+7.2%
Expenditure
1.2K
+51.6%+4.6%
Net Profit
55.05
+63.1%+138.9%
OPM %
6.79%
-0.83pp+1.84pp

Shareholding

Pattern breakdown

P/L Trends

(in crores)

RevenueExpenditureNet Profit
-193.56207.14607.851.0K1.4KQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Price Chart
Reports

Indo Rama Q2: consolidated PAT triples YoY on margin recovery; spread cools from Q1

polyester · margin recovery · festive season volumes

ResultsQ2 FY2716 Oct 20263 minConsumer & Retail

Margin Recovery Redux—Can Q2 Hold the Spread?

polyester · margins · spreads

Result previewQ2 FY2711 Oct 20263 minConsumer & Retail

Indo Rama Q1FY27: PAT up 21% YoY to ₹63.7 Cr as margins expand on 28% revenue drop

polyester · margin expansion · revenue decline

ResultsQ1 FY2729 Jul 20263 minConsumer & Retail
Latest
Board Meeting16 Oct, 2:58 pm

Indo Rama Q2: consolidated PAT triples YoY on margin recovery; spread cools from Q1

Indo Rama Synthetics' consolidated net profit for Q2 FY27 (quarter ended 30 September 2026) came in at ₹74.08 Cr, up 202% YoY from ₹24.55 Cr in Q2 FY26, on consolidated revenue of ₹1,340.64 Cr (+9.8% YoY). Standalone PAT was ₹55.05 Cr, up 139% YoY on revenue of ₹1,248.33 Cr (+7.0% YoY) — standalone profit growth trails the consolidated number by roughly 60 percentage points, meaning the four subsidiaries (Indorama Ventures Yarns, Indorama Yarns, Indorama Sustainable Polymers, Indorama Sustainable Polyester Yarns) drove a disproportionate share of the group's profit gain this quarter. Both bases were already profitable a year ago, so this is a margin-led acceleration rather than a loss-to-profit turnaround. The gain is margin-driven: consolidated operating margin (EBITDA excluding other income, over revenue) expanded to ~8.5% from 5.6% a year ago, and net margin to ~5.5% from 2.0% — consistent with the industry-wide polyester-spread recovery flagged in our pre-result preview. But the spread did not fully hold sequentially: Q1 FY27 had posted a sharper OPM of ~10.8% and NPM of 6.8%, so margins cooled from that peak even as a 43% QoQ revenue jump (festive-season volume pickup) diluted rather than improved the margin profile. Standalone EBITDA of ₹93.1 Cr and NPM of ~4.4% both came in below the ₹100–120 Cr EBITDA / 6–7% NPM band we flagged pre-result, while standalone revenue of ₹1,248 Cr beat the ₹880–950 Cr expected range — a beat on volume, a miss on the margin question that was the central watch item going in. There is no tracked analyst consensus for this stock — coverage is thin, as flagged pre-result (no analyst ratings in the prior three months) — so the vs-street read here is judged against our own preview range rather than a published estimate; management has issued no formal FY27 or H2 guidance on record, and no press release beyond the regulatory filing was available to cross-check management's own framing of the quarter. H1 FY27 consolidated revenue is still down 9.9% YoY at ₹2,277 Cr, dragged by a weak Q1 (revenue had fallen sharply that quarter), even as H1 PAT rose 78% YoY to ₹137.8 Cr — underscoring that the YoY profit recovery across the half is margin-driven, not volume-driven. During the quarter the promoter bought 4,14,796 shares (10 September 2026) alongside a stock-price-movement clarification filing, and the company closed its trading window on 28 September ahead of today's board meeting; neither development carries a quantifiable P&L link disclosed in this filing.

16 Oct 2026, 02:58 pm

Corporate Events

Board MeetingINDORAMA
2026
16Oct

Board Meeting

The Board of Directors meeting is scheduled to consider and …

BSE Filing ↗
Board MeetingINDORAMA
2026
8Sep

Board Meeting

The 40th Annual General Meeting of the Company will be held …

BSE Filing ↗
Board MeetingINDORAMA
2026
29Jul

Board Meeting

The meeting of the Board of Directors will be held to consid…

BSE Filing ↗
Board MeetingINDORAMA
2026
25May

Board Meeting

The board meeting is scheduled to consider and approve the a…

BSE Filing ↗
Board MeetingINDORAMA
2026
31Jan

Board Meeting

Consider and approve Un-audited Standalone and Consolidated …

BSE Filing ↗
Board MeetingINDORAMA
2025
10Nov

Board Meeting

Consider and approve Unaudited Standalone and Consolidated F…

BSE Filing ↗
Board MeetingINDORAMA
2025
14Aug

Board Meeting

Consider and approve the Un-audited Standalone and Consolida…

BSE Filing ↗
Board MeetingINDORAMA
2025
13May

Board Meeting

Consider and approve the Audited Standalone and Consolidated…

BSE Filing ↗
Board MeetingINDORAMA
2025
7Feb

Board Meeting

Consider and approve the Un-audited Standalone and Consolida…

BSE Filing ↗
Board MeetingINDORAMA
2025
6Feb

Board Meeting

Consider and approve Un-audited Standalone and Consolidated …

BSE Filing ↗
Board MeetingINDORAMA
2024
9Nov

Board Meeting

Consider Un-audited Standalone and Consolidated Financial Re…

BSE Filing ↗
Board MeetingINDORAMA
2024
17May

Board Meeting

Consider and approve Audited Results

BSE Filing ↗
Board MeetingINDORAMA
2024
8Feb

Board Meeting

Consider and approve Quarterly Results for the Third Quarter…

BSE Filing ↗
Board MeetingINDORAMA
2023
7Nov

Board Meeting

Consider and approve Un-audited Standalone and Consolidated …

BSE Filing ↗